Abeona Therapeutics Inc.
ABEO Healthcare Biotechnology
Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ABEO
Abeona Therapeutics Inc. (ABEO) P/E ratio
Abeona Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.8× (August 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 4.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 3.6× | (10.91%) |
| Dec 2025 | 4.0× | (24.92%) |
| Jun 2025 | 5.4× | — |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABEO Abeona Therapeutics Inc. | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| EYPT EyePoint, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| PALI Palisade Bio, Inc. compare | 2.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)